Introduction
Neutralization of a virus (reviewed by Dimmock, 1993 Dimmock, , 1995 can be broadly defined as the loss of infectivity which results from binding of antibody to epitope(s) on the surface of the particle. It may require no other agent, but can be assisted or be entirely dependent upon additional factors such as complement or cells bearing Fc receptors. Contrary to common belief, IgG rarely neutralizes by steric inhibition of contact between the virus attachment site and its cell receptor, which has been documented only for a few viruses and certain of their MAbs [Newcastle disease virus: Iorio et al., 1989 ; rhinovirus type 14: Colonno et aI., 1989; Smith et al., 1993;  human immunodeficiency virus type 1 (HIV-1): Posner el al., 1991; influenza A virus: Outlaw & Dimmock, 1993] . Usually, neutralizing antibodies inhibit a stage of infection which occurs after attachment of neutralized virus to the host cell, either Author for correspondence: S. J. Armstron 9.
Fax +44 1203 523568, e-mail LL@DNA.Bio,Warwick, ac.uk virus entry (such as virus-cell membrane fusion either at the plasma membrane or within endosomal vesicles), or a postentry event (Dimmock, 1993 (Dimmock, , 1995 . Antibody may also reduce infection before attachment of virus to the cells by aggregating virions, or causing virions to disintegrate under physiological conditions, or non-physiological conditions such as low ionic strength or temperatures of 39 °C (Boey6 el al., 1994; Dimmock, 1995) .
Some antibodies are capable of post-attachment neutralization (PAN), defined as the reduction in number of infectious centres achieved by antibody reacting with virus that has already attached to cells but has not yet been internalized.
There are examples of MAbs and polyclonal antisera giving PAN with a wide variety of different viruses (influenza A virus : Ishada & Ackerman, 1956; Newcastle disease virus: Russell, 1984; enterovirus 71 : Kjell6n, 1985 ; West Nile virus: Gollins & Porterfield, 1986; rabies virus: Dietzschold et al., 1987; vesicular stomatitis virus: Blumenthal et al., 1987 ; Venezuelan equine encephalitis virus : Roehrig et al., 1988 ; adenovirus type 2: Wohlfart, 1988 , 1989 Arendrup et al., 1993; human cytomegalovirus: Ohizumi et al., 1992 ; poliovirus type 1: Vrijsen et al., 1993; respiratory syncytial virus : Osiowy & Anderson, 1995) . There is little understanding of how PAN is effected but it is known to increase elution of attached virus (Dietzschold et al., 1987) , or inhibit fusion (Gollins & Porterfield, 1986; Blumenthal et al., 1987) , or permit entry of virus into the host cell but prevent conversion of the 160S virion to a I35S particle (Vrijsen et al., 1993) . PAN with poliovirus type I depends on bivalent attachment of IgG (Vrijsen et al., 1993) . In general, MAbs to different epitopes vary greatly in their PAN-ability but polyclonal antisera investigated above usually gave PAN, suggesting that PAN epitopes are strongly immunogenic. PAN can also be dependent upon cryptic epitopes which are revealed only after virus has attached to the host cell (Kjell6n, 1985) . Neutralizing antibodies to HIV-1 are directed against a variety of epitopes present on the distal and proximal elements of the envelope protein, gp120 and gp41. Antibodies produced early in human infection are usually strain specific and directed against the highly variable V3 loop of gp120, while later antibodies are more cross-reactive and directed mainly to the conserved CD4-binding site but also to the relatively conserved tip of the V3 loop (McKeating, 1992; ).
There have been few studies of the mechanisms by which anti-HIV-1 antibodies neutralize. MAbs to the CD4-binding site are defined by their ability to block attachment of soluble rgp120 to soluble CD4, and it has been suggested that they act by blocking attachment of virus to susceptible host cells. Human post-infection/immunization sera are known to block attachment of HIV-1 to cells (McDougal et al., 1986; Ho et al., 1988; Skinner et al., 1988; Montefiori et al., 1993) , but the epitope specificity of the antibodies responsible has not yet been determined. Study of MAbs is more informative. Several CD4-binding site antibodies reduced attachment to cells (Sun et al., 1989; Posner et al., 1991) , but only data with Posner's F105 MAb correlated with the extent of neutralization.
The antibodies used in the study described here were the gp120 neutralizing MAbs ICR39.3b, ICR39.13g (both CD4binding site-specific; rat IgG2b), and ICR41.Ii (V3 loopspecific; rat IgG2c: Cordell et al., 1991; McKeating et al., 1992a) . FACS analysis in our laboratory has shown that none of them inhibited attachment of virus to the CD4 receptor, and this was controlled by MAb F105 (Posner et al, 1991) which, under the same conditions, inhibited attachment in proportion to neutralization. Neutralized virus which attached to cells did so via the CD4 receptor, as it was inhibited by MAb Q4120 which blocks attachment of non-neutralized virus to CD4 (Healy et al., 1990; L. McLain, unpublished data) . Thus, data showing that CD4-binding site-specific MAbs interfere with binding of soluble (s) gp120 and sCD4 (Cordell et al., 1991) and that their epitopes overlap the CD4-binding site on gp120 (McKeating et al., 1992 b; Thali et al., 1993) do not necessarily predict their effect on virus particles. Inhibition of attachment of virus to CD4 by MAb F105 may occur because its epitope overlaps more of the CD4-binding site than do the epitopes of ICR39.3b and ICR39.13g (Thali et al., 1992) . In other studies, we have established that neutralization by ICR39.13g correlates closely with inhibition of virus-mediated cell fusion and internalization of the virion core p24 protein. However, ICR39.3b and ICR41.1i allow normal entry and therefore appear to affect a post-internalization step in infection (unpublished data). To further characterize the mechanisms of neutralization, we examine here the ability of these antibodies to effect PAN.
Methods
• Cells and virus. Hybridomas were cultured under standard conditions (McLain & Dimmock, 1994) . MAbs were purified using protein G-Sepharose (Gammabind Plus; Pharmacia) and their concentrations measured by absorbance at 280 nm. HIV-1 IIIB was obtained from the supernatant of persistently infected H9 cells (MRC ADP Reagent Programme) by co-culture with non-infected H9 cells, and purified on a Sephacryl S-I000 Superfine column (Pharmacia) to remove flee gp120. Infectivity was assayed on C8166 cells by syncytiuminhibition (McLain & Dimmock, 1994) .
• Neutralization and PAN. Standard neutralization was performed by incubating 100 s.f.u. (syncytia forming units) of HIV-1 in 100 ill with 10 Ill of diluted antibody for I h at 37 °C in a 96-well plate. C8160 cells (2 x 104 cells/100 ill) were then added and the extent of neutralization determined by counting syncytia after incubation for 3 days at 37 °C and calculating growth of treated virus as a percentage of the virus control. This correlated well with the extent of neutralization obtained when synthesis of p24 antigen was assayed. To measure PAN, I x 10 ~ cells were incubated with 1000 s.f.u. HIV-1 in 500 ill of medium at room temperature for 1"5 h, and then washed three times to remove unbound virus. These conditions were chosen to obtain attachment of virus with minimum internalization. Cells were resuspended in dilutions of MAb in medium and incubated at the chosen temperature for 2 h. Free virus and MAb were removed by washing three times. Cells were then suspended in I ml of medium and dispensed into five replicate wells in a 96-well plate. Incubation was continued for 3 days at 37 °C, and neutralization determined as above.
Results

Post-attachment neutralization at 21 and 35 °C
Standard neutralization and PAN were determined at 21 and 35 °C using the same concentrations of MAbs. Fig. 1 shows that MAb ICR39.13g gave strong PAN at both temperatures, although this was not quite as inhibitory as standard neutralization. On the other hand, MAb ICR39.3b gave no PAN at either temperature although immunofluorescence studies, using biotinylated anti-rat IgG and streptavidin-fluorescein conjugate, demonstrated that the MAb bound to virus which had been pre-attached to cells at either temperature. Normal rat IgG used as a control was not detectable under similar conditions (data not shown). MAb For standard neutralization, serial dilutions of NAb were incubated with virus before inoculating onto C8166 cells (n). For PAN, virus was first allowed to attach to cells at 21 °C for 1-5 h and then, after washing, dilutions of MAbs were added for a further 2 h at 21 ( 0 ) or 35 °C (~(~-). Cells were then washed and incubated for 3 days at 37 °C. The mean neutralization (from two experiments) is expressed as a percentage of the virus control. Fig. 1) and hence occupied an intermediate position. However, immunofluorescence studies showed that this MAb bound to cell-attached virus at both temperatures (unpublished data). 
ICR41.1i gave PAN only at 21 °C (
Temperature requirements for PAN
In order to determine more precisely the temperature requirements of PAN, we used a single concentration of each of the MAbs (giving about 95 % neutralization) at 4, 21, 24, 26 and 35 °C. Virus was allowed to attach to cells at 4 °C for the investigation of PAN at 4 °C, and at 21 °C for investigation of PAN at higher temperatures. Fig. 2 only at temperatures of 24 °C and below, with an abrupt shift between 26 °C (no PAN) and 24 °C.
Time required for virus to become resistant to neutralization by ICR41 .li at 35 °C
Since PAN by MAb ICR41.1i was inhibited by incubation at 35 °C it was of interest to see how quickly the block occurred. Virus was allowed to attach to cells at 21 °C, and the temperature raised to 35 °C. MAbs were then added at various times after the temperature shift. Neutralization by ICR39.13g decreased linearly with time of addition and, by 2 h, 90 % of virus was no longer neutralized (Fig. 3) . The curve closely resembled the virus internalization curve obtained by measuring the resistance of virion p24 to removal from the cell by treatment with dithiothreitoI (unpublished data), suggesting that internalization was responsible for the resistance of virus to this antibody. In contrast, virus was > 95 % refractory to neutralization by ICR4I.li within 30 min of the temperature shift (Fig. 3) . This defines the time required to complete a temperature-sensitive change that resulted from its attachment to CD4.
Discussion
ICR39.3b, a CD4-binding site MAb, neutralizes only if it binds to the gp120 oligomer before the virus attaches to the cell. MAb ICR39.13g gave PAN at all temperatures from 4 to 35 °C, and thus is in total contrast to ICR39.3b although the MAbs have similar epitopes (see below). Evidently, neutralization epitopes of ICR39.13g are not obscured when virus attaches to the cell. ICR39.Idg does not inhibit attachment of neutralized virus to CD4 receptors, but inhibits internalization and virus fusion/entry in parallel with neutralization (S. J. Armstrong and others, unpublished data). Here, there is a parallel with some antibodies to other enveloped viruses which also exhibit PAN and neutralize by inhibiting fusion (West Nile flavivirus: Gollins & Porterfield, 1986; vesicular stomatitis virus: Blumenthal et al., 1987) . PAN of HIV-1 has also been demonstrated with a CD4-specific MAb (Rieber et al., 1992) . Possibly this MAb and ICR39.13g both act by interfering in the interaction between gp120 and CD4 during fusion.
The epitopes of MAbs ICR39.db and ICR39.13g overlap the edge of the CD4-binding site but are not identical with it (McKeating et al., 1992 b) . They map closely together, but can be distinguished by differences in the amount of neutralization of HIV-1 strains IIIB and MN, their binding to strain CBL4, the amount needed to block sgp120-sCD4 binding, and the effect on their binding of the mutation Leu 125 --+ Gly in the V1/V2 region of gp120 (Cordell eta]., 1991; McKeating et al., I992 b) . It is therefore not impossible that ICR39.db and ICR39.13g interact differently with virus. It will be of interest to determine if they also differ in their ability to cross-link gp I20 monomers, and parallel the human IgG1 MAb b12 which inhibits HIV-1-mediated cell fusion, and its monovalent Fab which does not (T. L. Mclnerney and others, unpublished) .
The Vd-specific MAb ICR41.1i gave PAN only at temperatures of 24 °C and below. This observation may be linked with observations of a temperature-dependent shift from low to high affinity binding of sgp120 to sCD4 (Moore & Klasse, 1992) , or a transition in binding of gp120 oligomers to sCD4 with no change in affinity (Dimitrov et al., 1992) . Fusion of CHO cells expressing gpI60 to cells expressing CD4, as assayed by mixing of membrane lipids, occurred only at temperatures above 25 °C (Frey et al., 1995) , although cell--cell binding occurred at lower temperatures. Cooption of CD4 molecules occurred at 37 °C and was cytoskeleton-dependent. These findings may reflect a temperature-dependent conformational change of CD4-bound gpI20 which is a prerequisite of membrane fusion. This movement may also mask the epitope for ICR41.1i, so that neutralization is no longer possible or, alternatively, the function which is inhibited by the MAb may have already been triggered at 26 °C and above, possibly by a conformational change, so that subsequent binding of MAb ICR41.1i has no neutralizing effect. Immunofluorescence data indicated that MAb ICR41.1i was able to bind to virus pre-attached to C8166 cells at 35 °C. However, this does not distinguish between antibody that binds to gp120 spikes that are involved in the initial contact with CD4 from antibody bound to the majority of gp120 spikes. This proviso applies both to ICR41.1i, as the temperature-dependent stage precedes membrane fusion (Frey et al., 1995) , and to ICR39.3b, as neutralization only occurs if the MAb binds to the virus before it attaches to the cell.
In conclusion, of three MAbs which give standard neutralization, we find that (i) MAb ICR39.db gave no PAN, (ii) MAb ICR41.li gave PAN only when it bound to virus at temperatures of 24 °C and below, and (iii) MAb ICR39.13g gave PAN at all temperatures between 4 and 35 °C. Binding of viral gp120 to cellular CD4 initiates a cascade of events, including conformational changes in both molecules, which results in the initiation of a fusion pore and its subsequent expansion with cooption of more gpi20 and CD4 units. We suggest that some of these initial changes may activate functions of the virus in preparation for infection of the cell and that ICR39.db and ICR41.1i act by interfering with the gp120-CD4 complex at specific, but different, points in their interactive pathway with the result that the internalized virus is inactive. Once that point is passed, these MAbs no longer neutralize even though they still bind to virus. In contrast, the major effect of ICR39.13g is to inhibit fusion during the expansion of the fusion pore, and this is reflected in the susceptibility of virus to PAN by this MAb until the virus is internalized. Clearly, PAN bears no relationship to the neutralization rate constants derived from standard neutralization where the order was ICR41.1i > ICR39.I3g > ICR39.3b (McLain & Dimmock, I994) . If PAN acts in vivo, only one of the three antibodies studied here will be able to 40C neutralize virus after it has attached to cells. It is evident that B cell-stimulating vaccines should stimulate antibodies that give both PAN and standard neutralization, particularly since the time for 50 % entry of HIV-i pre-attached to cells is around lb. S.J.A was supported by the Medical Research Council's AIDS Directed Programme. We thank Dr H. Holmes of the Reagent Repository of the Medical Research Council's AIDS Directed Programme (National Institute for Biological Standards and Control, Potters Bar, Herts) for the gift of several reagents and Ms J. Cordell (Institute for Cancer Research, Sutton, Surrey) for the gift of the monoclonal antibodies.
